Literature DB >> 23390112

Longitudinal study of levodopa in Parkinson's disease: effects of the advanced disease phase.

Ganesvaran Ganga1, Jane E Alty, Benjamin G Clissold, Craig D McColl, Katrina A Reardon, Mark Schiff, Peter A Kempster.   

Abstract

Thirty-four patients have been studied from the time of initiation of pharmacological treatment in a long-term prospective study of levodopa effects and disease progression in Parkinson's disease. Objective motor scoring of the response to levodopa in defined off states was performed every 3 years. The mean time from the initiation of levodopa treatment to the most recent measurements was 18.2 years. Of 8 patients who are still alive, only 3 had none of the features of the advanced disease phase (dementia, hallucinations, frequent falling). Off-phase motor function worsened at a yearly rate of 1.9% of the maximum disability score, although the plots of the serial scores showed that the magnitude of the levodopa response is well preserved. There was little difference in the rate of progression between patients with tremor-dominant and non-tremor-dominant motor subtypes. Those who developed dementia had more rapid deterioration of motor scores, with significantly worse off-phase (P = .008) and on-phase (P = .03) motor function. A graph of serial scores of patients who have died, aligned for time of death, showed an upward curving trend of motor disability in the last 5 years of the disease course. Its advanced phase may reveal that Parkinson's disease has an exponential pattern of progression.
Copyright © 2013 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23390112     DOI: 10.1002/mds.25335

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

Review 1.  The missing, the short, and the long: Levodopa responses and dopamine actions.

Authors:  Roger L Albin; Daniel K Leventhal
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

2.  Predictors of cognitive impairment in an early stage Parkinson's disease cohort.

Authors:  Michele T M Hu; Konrad Szewczyk-Królikowski; Paul Tomlinson; Kannan Nithi; Michal Rolinski; Clara Murray; Kevin Talbot; Klaus P Ebmeier; Clare E Mackay; Yoav Ben-Shlomo
Journal:  Mov Disord       Date:  2014-01-06       Impact factor: 10.338

3.  Prediction of the Levodopa Challenge Test in Parkinson's Disease Using Data from a Wrist-Worn Sensor.

Authors:  Hamid Khodakarami; Lucia Ricciardi; Maria Fiorella Contarino; Rajesh Pahwa; Kelly E Lyons; Victor J Geraedts; Francesca Morgante; Alison Leake; Dominic Paviour; Andrea De Angelis; Malcolm Horne
Journal:  Sensors (Basel)       Date:  2019-11-25       Impact factor: 3.576

4.  Effect of Age and Disease Duration on the Levodopa Response in Patients with Advanced Parkinson's Disease for Deep Brain Stimulation of the Subthalamic Nucleus.

Authors:  Dursun Aygun; Ersoy Kocabicak; Mustafa Onur Yildiz; Yasin Temel
Journal:  Front Neurol       Date:  2016-06-27       Impact factor: 4.003

5.  Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease.

Authors:  Marcus Pieterman; Scott Adams; Mandar Jog
Journal:  Front Neurol       Date:  2018-05-17       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.